| dbo:abstract |
Laquinimod je experimentální imunomodulátor, vyvíjený farmaceutickými společnostmi a Teva Pharmaceuticals. Je určen k perorální léčbě pacientů s roztroušenou sklerózou (RS). Jeho chemický vzorec je C19H17ClN2O3. Laquinimod je nástupcem neúspěšného experimentálního imunomodulátoru , vyvíjeného rovněž společností Active Biotech. Imunomodulátor byl zkoumán ve dvou studiích ve II. fázi klinických testů za využití opakovaných snímků magnetické rezonance (MRI). Podle výsledků se zdá být laquinimod schopný redukovat aktivitu RS. U obou studií se však projevily odlišné reakce na podanou dávku laquinimodu. Od roku 2008 je imunomodulátor ve III. fázi klinických testů. (cs) Laquinimod is an experimental immunomodulator developed by Active Biotech and Teva. It is being investigated as an oral treatment for multiple sclerosis (MS). Laquinimod is the successor of Active Biotech's failed experimental immunomodulator linomide. The compound has been investigated in two Phase II trials using successive magnetic resonance scans (MRI). Laquinimod seems to be able to reduce the MS disease activity on MRI. However, the response to a given dose was discrepant between both studies. Phase III studies for MS started in December 2007. In 2011, Teva announced its clinical trials involving laquinimod had failed, being unable to significantly reduce relapses in MS among patients beyond a placebo. However, the final results of above-mentioned phase III trial proved oral laquinimod administered once daily slowed the progression of disability and reduced the rate of relapse in patients with relapsing–remitting multiple sclerosis. On May 7, 2013 laquinimod was approved by the Russian Ministry of Health (the FDA analog) as a treatment for relapsing-remitting multiple sclerosis (RRMS) under the brand name Nerventra. (en) |
| dbo:iupacName |
5-Chloro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide (en) |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Laquinimod.svg?width=300 |
| dbo:wikiPageExternalLink |
http://clinicaltrials.gov/search/intervention=laquinimod |
| dbo:wikiPageID |
12511156 (xsd:integer) |
| dbo:wikiPageLength |
7062 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1026574887 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Roquinimex dbr:Ministry_of_Health_(Russia) dbr:Multiple_sclerosis dbr:Magnetic_resonance_imaging dbc:Immunosuppressants dbr:Food_and_Drug_Administration dbr:Immunomodulator dbr:Teva_Pharmaceutical_Industries dbr:Management_of_multiple_sclerosis |
| dbp:imagefile |
Laquinimod.svg (en) |
| dbp:pin |
5 (xsd:integer) |
| dbp:verifiedfields |
changed (en) |
| dbp:verifiedrevid |
462089089 (xsd:integer) |
| dbp:watchedfields |
changed (en) |
| dbp:wikiPageUsesTemplate |
dbt:Antineoplastic-drug-stub dbt:Chembox dbt:Chembox_Hazards dbt:Chembox_Identifiers dbt:Chembox_Properties dbt:Huh? dbt:Reflist dbt:Cascite dbt:Chembox_Pharmacology dbt:Chemspidercite dbt:Ebicite dbt:Fdacite dbt:Stdinchicite dbt:Multiple_sclerosis dbt:Immunosuppressants |
| dct:subject |
dbc:Immunosuppressants |
| gold:hypernym |
dbr:Immunomodulator |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q11173 yago:Agent114778436 yago:CausalAgent100007347 yago:Drug103247620 yago:Immunosuppressant103562958 yago:Matter100020827 yago:Medicine103740161 yago:PhysicalEntity100001930 yago:WikicatImmunosuppressants dbo:ChemicalCompound dbo:Drug yago:Substance100020090 umbel-rc:ChemicalSubstanceType |
| rdfs:comment |
Laquinimod je experimentální imunomodulátor, vyvíjený farmaceutickými společnostmi a Teva Pharmaceuticals. Je určen k perorální léčbě pacientů s roztroušenou sklerózou (RS). Jeho chemický vzorec je C19H17ClN2O3. Laquinimod je nástupcem neúspěšného experimentálního imunomodulátoru , vyvíjeného rovněž společností Active Biotech. Od roku 2008 je imunomodulátor ve III. fázi klinických testů. (cs) Laquinimod is an experimental immunomodulator developed by Active Biotech and Teva. It is being investigated as an oral treatment for multiple sclerosis (MS). Laquinimod is the successor of Active Biotech's failed experimental immunomodulator linomide. The compound has been investigated in two Phase II trials using successive magnetic resonance scans (MRI). Laquinimod seems to be able to reduce the MS disease activity on MRI. However, the response to a given dose was discrepant between both studies. (en) |
| rdfs:label |
Laquinimod (cs) Laquinimod (en) |
| owl:sameAs |
freebase:Laquinimod yago-res:Laquinimod wikidata:Laquinimod http://azb.dbpedia.org/resource/ایزتیونیک_اسید dbpedia-cs:Laquinimod dbpedia-fa:Laquinimod dbpedia-sh:Laquinimod dbpedia-sr:Laquinimod https://global.dbpedia.org/id/3DUGY |
| prov:wasDerivedFrom |
wikipedia-en:Laquinimod?oldid=1026574887&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Laquinimod.svg |
| foaf:isPrimaryTopicOf |
wikipedia-en:Laquinimod |
| is dbo:wikiPageRedirects of |
dbr:C19H17ClN2O3 dbr:ATC_code_N07XX10 dbr:ATCvet_code_QN07XX10 |
| is dbo:wikiPageWikiLink of |
dbr:C19H17ClN2O3 dbr:ATC_code_N07XX10 dbr:ATCvet_code_QN07XX10 dbr:Teva_Pharmaceuticals dbr:ATC_code_N07 dbr:Management_of_multiple_sclerosis dbr:Science_and_technology_in_Israel dbr:Multiple_sclerosis_drug_pipeline dbr:Multiple_sclerosis_research |
| is foaf:primaryTopic of |
wikipedia-en:Laquinimod |
